Calming mast cells: triggers, medical care & evidence
N. Thornton, MSc. · Molecular Biologist · 8 min · RARE Labs
Editorially updated:
7 scientific sources · References“Calming mast cells”: what it means, the role of individual triggers and medical care, and what nutrient studies do not establish.
Scientific context, not supplementation advice or a claim about any RARE product. This article does not replace medical advice.
What does “calming mast cells” mean?
Mast cells are immune cells in skin, mucosa and connective tissue. When activated they release histamine, tryptase, prostaglandins and cytokines. In research, “calming” means two things: less activation by triggers and a more stable cell that releases fewer mediators. The basics are covered in our article “Understanding mast cells”.
Individual triggers and dietary histamine
The first level is avoiding individual triggers. In their guide, Afrin et al. (2016) list typical triggers such as heat, cold, pressure, friction, exertion, alcohol, certain drugs, odours and stress; which apply is highly individual. Where dietary histamine is a factor, the low-histamine diet comes in, which we have assessed separately.
Medical care is not a supplement promise
The second level is medical. Molderings et al. (2016) summarised pharmacological options — including H1 and H2 antihistamines, mast cell stabilisers such as cromolyn and leukotriene antagonists — and recommend a stepwise, individual approach. This therapy belongs in medical hands and cannot be replaced by supplements.
Quercetin, luteolin and vitamin D: what cell studies tell us
The third level is nutrient research. Flavonoids are best studied: Kempuraj et al. (2005) showed in human mast cells that quercetin inhibited release of inflammatory mediators, and Tsilioni and Theoharides (2024) reported stronger inhibition by luteolin than by cromolyn — both in cell culture. Theoharides et al. (2015) also discussed luteolin in the context of mast cells in the nervous system and “brain fog”.
Vitamin D is studied too: Yip et al. (2014) showed that vitamin D3 metabolites dampened IgE-dependent mast cell activation via the vitamin D receptor — in mouse cells and an animal model. Kaag and Lorentz (2023) summarise further dietary components and name the poor bioavailability of many compounds as the core problem.
What cannot be concluded from this research
The honest summary: trigger management and medical therapy are the two levels with clinical experience. Nutrient research provides consistent mechanisms in cells but no evidence from controlled human studies in mast cell activation. Which compounds have been studied and where the data stop is laid out in our article on MCAS and supplements.
Study design at a glance
- Type
- Overview (therapy recommendations, reviews, cell and animal studies)
- Participants
- patients with mast cell activation, human mast cell cultures, mice
- Duration
- 2005–2024
What this means — and what it does not
- “Calming mast cells” covers three levels: avoiding triggers, medical therapy and nutrient research.
- Triggers are individual; a symptom diary helps identify them.
- Medications such as antihistamines and mast cell stabilisers belong in medical hands.
- Quercetin, luteolin and vitamin D show mechanisms in cell and animal studies; clinical evidence is lacking.
Limitations
- Nutrient findings come mostly from cell cultures and animal models and do not translate to humans.
- No health claim authorised in the EU refers to mast cells or MCAS.
- Symptoms suggesting mast cell activation require medical assessment.
- This article provides scientific information and makes no claim about the effect of any RARE product.
Sources
- Afrin LB et al., Ann Med 2016 — Often seen, rarely recognized: mast cell activation disease — a guide to diagnosis and therapeutic optionsAfrin LB, Butterfield JH, Raithel M et al. · Ann Med · 2016 · PMID: 27012973
- Molderings GJ et al., Naunyn Schmiedebergs Arch Pharmacol 2016 — Pharmacological treatment options for mast cell activation diseaseMolderings GJ, Haenisch B, Brettner S et al. · Naunyn Schmiedebergs Arch Pharmacol · 2016 · PMID: 27132234
- Kempuraj D et al., Br J Pharmacol 2005 — Flavonols inhibit proinflammatory mediator release, intracellular calcium ion levels and protein kinase C theta phosphorylation in human mast cellsKempuraj D, Madhappan B, Christodoulou S et al. · Br J Pharmacol · 2005 · PMID: 15912140
- Tsilioni I, Theoharides TC, Int Arch Allergy Immunol 2024 — Luteolin Is More Potent than Cromolyn in Their Ability to Inhibit Mediator Release from Cultured Human Mast CellsTsilioni I, Theoharides T · Int Arch Allergy Immunol · 2024 · PMID: 38588651
- Theoharides TC et al., Front Neurosci 2015 — Brain "fog," inflammation and obesity: key aspects of neuropsychiatric disorders improved by luteolinTheoharides TC, Stewart JM, Hatziagelaki E et al. · Front Neurosci · 2015 · PMID: 26190965
- Yip KH et al., J Allergy Clin Immunol 2014 — Mechanisms of vitamin D₃ metabolite repression of IgE-dependent mast cell activationYip KH, Kolesnikoff N, Yu C et al. · J Allergy Clin Immunol · 2014 · PMID: 24461581
- Kaag S, Lorentz A, Cells 2023 — Effects of Dietary Components on Mast Cells: Possible Use as Nutraceuticals for Allergies?Kaag S, Lorentz A · Cells · 2023 · PMID: 37998337
Editorial note: these articles are contextual knowledge pieces and do not replace medical advice.
Our products are foods (food supplements), not medicinal products. They are not intended to prevent, treat or cure any disease. If you have symptoms, pre-existing conditions, are pregnant or breastfeeding, or take medication, please consult your doctor or pharmacist.